Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial

John F. Tisdale; Francis J. Pierciey; Melissa Bonner; Alexis A. Thompson; Lakshmanan Krishnamurti; Markus Y. Mapara; Janet L. Kwiatkowski; Ilya Shestopalov; Jean Antoine Ribeil; Wenmei Huang; Mohammed Asmal; Julie Kanter; Mark C. Walters

doi:10.1002/ajh.25867

Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial

John F. Tisdale, Francis J. Pierciey, Melissa Bonner, Alexis A. Thompson, Lakshmanan Krishnamurti, Markus Y. Mapara, Janet L. Kwiatkowski, Ilya Shestopalov, Jean Antoine Ribeil, Wenmei Huang, Mohammed Asmal, Julie Kanter, Mark C. Walters^*

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Letter › peer-review

15 Scopus citations

Original language	English (US)
Pages (from-to)	E239-E242
Journal	American Journal of Hematology
Volume	95
Issue number	9
DOIs	https://doi.org/10.1002/ajh.25867
State	Published - Sep 1 2020

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.25867

Cite this

Tisdale, J. F., Pierciey, F. J., Bonner, M., Thompson, A. A., Krishnamurti, L., Mapara, M. Y., Kwiatkowski, J. L., Shestopalov, I., Ribeil, J. A., Huang, W., Asmal, M., Kanter, J., & Walters, M. C. (2020). Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial. American Journal of Hematology, 95(9), E239-E242. https://doi.org/10.1002/ajh.25867

@article{4dde31a1012342d0b61109ddb888efe6,

title = "Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial",

author = "Tisdale, {John F.} and Pierciey, {Francis J.} and Melissa Bonner and Thompson, {Alexis A.} and Lakshmanan Krishnamurti and Mapara, {Markus Y.} and Kwiatkowski, {Janet L.} and Ilya Shestopalov and Ribeil, {Jean Antoine} and Wenmei Huang and Mohammed Asmal and Julie Kanter and Walters, {Mark C.}",

note = "Funding Information: The authors thank the patients, their families, and caregivers for participating in the study. They would like to acknowledge staff members at all the HGB‐206 clinical sites: K. Hammond and J. Schneiderman at Ann and Robert H. Lurie Children{\textquoteright}s Hospital of Chicago; H.C. Kim, K. Smith‐Whitley, D. Teachey, T. Olson, J. Freedman, S. Grupp, Y. Wang, I. Sommers, and P. Venkatapuram at Children{\textquoteright}s Hospital of Philadelphia; and C. Bascon, A. Garcia, M. Moriarty, and A. Lal at UCSF Benioff Children{\textquoteright}s Hospital, Oakland. They would also like to acknowledge the following former and current bluebird bio employees and consultants: Alexandra Miller, Becky Price, Craig Jones, Erin Meister, Erin Whitney, Gretchen Lewis, Iva Kronja, Kyla MacLeod, Min Luo, Olivier Negre, Ren Chen, and Stef De Reys. Funding for this research was provided by bluebird bio, Inc. Medical writing support was provided by Patrice Ferriola (KZE PharmAssociates, LLC) and Peloton Advantage, LLC, and funded by bluebird bio. John F. Tisdale and Francis J. Pierciey Jr contributed equally to this work. ",

year = "2020",

month = sep,

day = "1",

doi = "10.1002/ajh.25867",

language = "English (US)",

volume = "95",

pages = "E239--E242",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "9",

}

Tisdale, JF, Pierciey, FJ, Bonner, M, Thompson, AA, Krishnamurti, L, Mapara, MY, Kwiatkowski, JL, Shestopalov, I, Ribeil, JA, Huang, W, Asmal, M, Kanter, J & Walters, MC 2020, 'Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial', American Journal of Hematology, vol. 95, no. 9, pp. E239-E242. https://doi.org/10.1002/ajh.25867

Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial. / Tisdale, John F.; Pierciey, Francis J.; Bonner, Melissa et al.

In: American Journal of Hematology, Vol. 95, No. 9, 01.09.2020, p. E239-E242.

Research output: Contribution to journal › Letter › peer-review

TY - JOUR

T1 - Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial

AU - Tisdale, John F.

AU - Pierciey, Francis J.

AU - Bonner, Melissa

AU - Thompson, Alexis A.

AU - Krishnamurti, Lakshmanan

AU - Mapara, Markus Y.

AU - Kwiatkowski, Janet L.

AU - Shestopalov, Ilya

AU - Ribeil, Jean Antoine

AU - Huang, Wenmei

AU - Asmal, Mohammed

AU - Kanter, Julie

AU - Walters, Mark C.

N1 - Funding Information: The authors thank the patients, their families, and caregivers for participating in the study. They would like to acknowledge staff members at all the HGB‐206 clinical sites: K. Hammond and J. Schneiderman at Ann and Robert H. Lurie Children’s Hospital of Chicago; H.C. Kim, K. Smith‐Whitley, D. Teachey, T. Olson, J. Freedman, S. Grupp, Y. Wang, I. Sommers, and P. Venkatapuram at Children’s Hospital of Philadelphia; and C. Bascon, A. Garcia, M. Moriarty, and A. Lal at UCSF Benioff Children’s Hospital, Oakland. They would also like to acknowledge the following former and current bluebird bio employees and consultants: Alexandra Miller, Becky Price, Craig Jones, Erin Meister, Erin Whitney, Gretchen Lewis, Iva Kronja, Kyla MacLeod, Min Luo, Olivier Negre, Ren Chen, and Stef De Reys. Funding for this research was provided by bluebird bio, Inc. Medical writing support was provided by Patrice Ferriola (KZE PharmAssociates, LLC) and Peloton Advantage, LLC, and funded by bluebird bio. John F. Tisdale and Francis J. Pierciey Jr contributed equally to this work.

PY - 2020/9/1

Y1 - 2020/9/1

UR - http://www.scopus.com/inward/record.url?scp=85085886270&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85085886270&partnerID=8YFLogxK

U2 - 10.1002/ajh.25867

DO - 10.1002/ajh.25867

M3 - Letter

C2 - 32401372

AN - SCOPUS:85085886270

SN - 0361-8609

VL - 95

SP - E239-E242

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 9

ER -

Tisdale JF, Pierciey FJ, Bonner M, Thompson AA, Krishnamurti L, Mapara MY et al. Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial. American Journal of Hematology. 2020 Sep 1;95(9):E239-E242. doi: 10.1002/ajh.25867

Safety and feasibility of hematopoietic progenitor stem cell collection by mobilization with plerixafor followed by apheresis vs bone marrow harvest in patients with sickle cell disease in the multi-center HGB-206 trial

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this